Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster

NCT04091451 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1430

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Zoster

Interventions

BIOLOGICAL: Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
DRUG: Placebo

Sponsor

GlaxoSmithKline